Ulrich Bartke Appointed to New Position of Vice President Global Sales & Marketing of Inyx

- Will Direct Intensified Sales Growth and Strategic Marketing Initiatives -

May 27, 2004, 01:00 ET from Inyx, Inc.

    NEW YORK, May 27 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board:  
 IYXI), an emerging specialty pharmaceutical company with a focus on niche drug
 delivery technologies and products, announced today that Ulrich Bartke, Ph.D.
 will be joining the company on June 1, 2004 in the newly established, senior
 management position of Vice President Global Sales & Marketing.
     "We are very pleased to have a person with Mr. Bartke's extensive and
 highly successful pharmaceutical business experience join Inyx," said Dr. Jack
 Kachkar, Inyx Chairman & CEO.  "Mr. Bartke's appointment is part of Inyx's
 evolution into an integrated specialty pharmaceutical company.  Through his
 direction and initiatives, Inyx's sales and marketing efforts should be
 significantly enhanced.
     "Initially, Mr. Bartke will focus on building Inyx's contract
 manufacturing revenues and increasing the utilization of production capacity,
 with the objective to increase sales and profitability," Dr. Kachkar informed.
 "Additionally, he will be cultivating strategic marketing relationships with
 key clients to handle the distribution of Inyx's own proprietary products,
 which we are now developing and plan to start to introduce in early 2005."
     "I am very pleased to be joining Inyx," said Mr. Bartke.  "Inyx has niche
 aerosol pharmaceutical development and production expertise that is needed in
 the marketplace today, particularly the proven ability to develop and produce
 non-ozone-depleting aerosol products.  I am looking forward to assisting in
 the growth of Inyx's business."
     Mr. Bartke will be based initially at the company's development and
 production center located in Cheshire, England, operated under its wholly
 owned subsidiary INyX Pharma Limited.  He will be directing the company's
 sales and marketing activities around the world, including in North America,
 Latin and South America and Asia as well as Europe.
     Ulrich Bartke, Ph.D.
     From 2001 to 2003, Mr. Bartke served as Vice President Global Sales &
 Marketing of PowderJect Pharmaceuticals Plc, where he directed sales growth
 from approximately $40 million to in excess of $290 million during his two-
 year tenure.  In June 2003, PowderJect, at the time a publicly owned company
 traded on the London Stock Exchange, was acquired by Chiron Corporation.
 Following this acquisition, Mr. Bartke became a consultant to the
 pharmaceutical industry, focusing on U.S. and European markets.
     Mr. Bartke began his professional career and served for 17 years, from
 1984 to 2001, with GlaxoSmithKline companies in a number of different
 executive capacities.  He started out in manufacturing management positions
 before moving into several marketing directorships at SmithKline Beecham
 Pharmaceuticals.  In his last position, he served as Therapy Area Director,
 Vaccines, for GSK Pharmaceuticals Europe.
     Mr. Bartke holds a BSc in Pharmacy and a Ph.D. in Pharmaceutical Chemistry
 from the University of Berlin.
     About Inyx
     Inyx, Inc. is an emerging specialty pharmaceutical company with niche
 aerosol drug delivery technologies and products.  Inyx focuses its expertise
 on contract manufacturing of prescription and over-the-counter pharmaceutical
 products, and provides specialty pharmaceutical development and production
 consulting services to the international healthcare market.  In addition, Inyx
 is developing its own proprietary products to be marketed by selected clients
 and strategic partners.  The company's operations are conducted through its
 wholly owned subsidiary, INyX Pharma Limited, with a focus on niche products
 and technologies for the treatment of respiratory, allergy, dermatological and
 topical conditions.  INyX Pharma's client base comprises large ethical
 pharmaceutical corporations, branded generic companies and biotechnology
 firms.  The company develops and manufactures for a majority of global
 markets, including:  North America, Europe, Latin America and the Middle East.
 INyX Pharma's R&D and production facilities are in Runcorn, near Manchester,
 England.  Another wholly owned subsidiary, Inyx Canada, Inc. based in Toronto,
 provides business development and support services.  Inyx, Inc.'s corporate
 offices are in New York City.
     Safe Harbor
     Statements about the Company's future expectations, including future
 revenues and earnings, and all other statements in this press release other
 than historical facts, are "forward-looking statements" within the meaning of
 Section 27A of the Securities Act of 1933, Section 21E of the Securities
 Exchange Act of 1934, and as that term is defined in the Private Securities
 Litigation Reform Act of 1995.  The Company intends that such forward-looking
 statements be subject to the safe harbors created thereby.  Since these
 statements involve risks and uncertainties and are subject to change at any
 time, the Company's actual results could differ materially from expected
     For more information, please contact:
      Jay M. Green, Executive VP
      Inyx, Inc.

SOURCE Inyx, Inc.